opnurasib,jdq443,tislelizumab
novartis,beigene
['kontrast-01', 'jdq443', 'sclc', 'nsclc']
#asco23 abs#9007
kontrast-01 update: safety and efficacy of jdq443 in kras g12c mt nsclc orr 41.7% across dls orr 54.5% at 200 mg bid
small study, ongoing studies with apd1 and shpi 
Leslye M. Heisler Associate Professor of Lung Cancer Excellence @PennMedicine | AD @PC31 | Incoming Chair @ASCO #CCC | Tweets my own | COI: https://t.co/ghKU8KhBvl